Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00809679
Recruitment Status : Terminated (Some patients experienced asymptomatic, transient elevations in liver transaminases)
First Posted : December 17, 2008
Last Update Posted : June 8, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of T-62 in subjects with postherpetic neuralgia.

Condition or disease Intervention/treatment Phase
Postherpetic Neuralgia Drug: T-62 Dose 1 Drug: T-62 Dose 2 Other: Placebo Phase 2

Detailed Description:
Study K862-08-2002 is a multicenter, randomized, double-blind, placebo-controlled study assessing the analgesic efficacy and safety of T-62 in subjects with postherpetic neuralgia (PHN) and its associated pain. Up to 20 centers in the United States will participate in the trial. Two doses of T-62 and placebo will be evaluated in parallel design. Approximately 130 subjects will be enrolled to complete approximately 100 subjects. Each subject will complete a 7-day Screening Period , a 28-day Treatment Period, and a 14-day Post-Treatment Period. Each subject will complete 8 clinic visits over the course of the study during which procedures and assessments of safety, efficacy, and protocol compliance will be performed.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled, Pilot Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia
Study Start Date : December 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shingles
U.S. FDA Resources

Arm Intervention/treatment
Experimental: T-62 100 mg bid Drug: T-62 Dose 1
Capsule dosage form 100 mg bid
Experimental: T-62 200 mg bid Drug: T-62 Dose 2
Capsule dosage form 200 mg bid
Placebo Comparator: Placebo Other: Placebo
Capsule dosage form placebo bid

Primary Outcome Measures :
  1. Change in pain scores from baseline to following treatment. [ Time Frame: weekly ]

Secondary Outcome Measures :
  1. General safety monitoring (adverse reactions, vital signs, electrocardiograms, clinical laboratories) [ Time Frame: weekly ]
  2. Pharmacokinetics [ Time Frame: weekly ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria (additional criteria apply):

  1. Diagnosis of PHN made by primary treating physician and is experiencing pain for at least 3 months after the healing of a herpes zoster rash.
  2. Subject is in general good health.
  3. Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control or be surgically sterile or post-menopausal. Double barrier methods and abstinence are the only acceptable birth control methods for this study.

Exclusion Criteria (additional criteria apply):

  1. Subject has a current acute disease or unstable chronic disease other than post herpetic neuralgia.
  2. Subject has a clinically important history of a medical disorder (particularly cardiovascular, neurological [e.g., diabetic neuropathy], respiratory, or hepato-biliary systems [e.g., Gilbert Syndrome]) that would confound and/or interfere with the safety and efficacy evaluations defined in the protocol.
  3. Subject is being treated for a medical condition that affects cardiac conduction.
  4. Subject's plasma alanine aminotransferase (ALT) aspartate aminotransferase (AST), total bilirubin, and alkaline phosphatase (AP) values are not within the normal reference ranges.
  5. Subject has a history of asthma requiring management for reactive airway disease in the last year.
  6. Subject uses and is unwilling/unable to discontinue use of (A) Lyrica® (pregabalin), Cymbalta® (duloxetine), Neurontin® (gabapentin), topical lidocaine, topical capsaicin, or other medication specifically indicated (i.e., labeled) for the treatment of neuropathic pain, or (B) anticonvulsant medications to control post herpetic neuralgia.
  7. Subject currently requires anticonvulsant medications to control seizures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00809679

United States, Arizona
Tucson, Arizona, United States
United States, California
Westlake Village, California, United States
United States, Florida
Bradenton, Florida, United States
Naples, Florida, United States
New Port Richey, Florida, United States
Sunrise, Florida, United States
Tampa, Florida, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, North Carolina
Winston-Salem, North Carolina, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Texas
San Antonio, Texas, United States
United States, Washington
Spokane, Washington, United States
Sponsors and Collaborators
Study Director: Robert L. Rolleri, Pharm. D. King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

Responsible Party: Pfizer Identifier: NCT00809679     History of Changes
Other Study ID Numbers: K862-08-2002
First Posted: December 17, 2008    Key Record Dates
Last Update Posted: June 8, 2012
Last Verified: June 2012

Keywords provided by Pfizer:
Postherpetic neuralgia
Varicella Zoster
Neuropathic pain

Additional relevant MeSH terms:
Neuralgia, Postherpetic
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs